Background Peginterferon–ribavirin therapy is the current standard of care for chronic
infection with hepatitis C virus (HCV). The rate of sustained virologic response has been …

Background In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who
do not have a sustained response to therapy with peginterferon–ribavirin, outcomes after …

BACKGROUND & AIMS: The addition of boceprevir to therapy with peginterferon alfa-2b
and ribavirin results in significantly higher rates of sustained virologic response (SVR) in …

A new era of therapy for hepatitis C virus (HCV) infection is dawning with the development of
two effective HCV protease inhibitors, boceprevir and telaprevir. In this issue of the Journal …

Background & Aims The safety profiles of boceprevir and telaprevir in the treatment of
chronic hepatitis C, administered in academic and community centres across the United …

The introduction of direct acting antiviral agents (DAAs) will markedly change treatment
options for individuals who have a chronic HCV infection. Within the next few months …

Background In patients with chronic infection with hepatitis C virus (HCV) genotype 1,
treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained …

The aim of this study is to review clinical trial data on the newly approved protease inhibitors
boceprevir and telaprevir to develop consensus recommendations on the optimal use of …

Background Current therapy for chronic hepatitis C virus (HCV) infection is effective in less
than 50% of patients infected with HCV genotype 1. Telaprevir, a protease inhibitor specific …

OBJECTIVE: To summarize and evaluate the published literature pertaining to boceprevir
and telaprevir, and to provide clinicians with suggestions for use in patients with chronic …